Genetic recombination of the neurovirulent A/NWS/cc-p (HONM) and the non-neurovirulent A/Jap.305/57 (H2N2) influenza viruses in which hemagglutinin and neuraminidase were segregated (HON2, H2N1) were studied for neurovirulence in mice immunosuppressed with cyclophosphamide (CPA) which permitted full expression of virulence. Both HON2 and H2N1 recombinants replicated in the brain (in contrast to the H2N2 parent) and both produced lethal effects in CPA-treated animals. Therefore we conclude that A/NWS (HONM) neurovirulence is not exclusively linked with either the hemagglutinin or the neuraminidase of the virus. The HON2 and H2N1 recombinants have revealed the existence of two separate attributes of neurovirulence: (i) the capacity of virus to initiate intracerebral infection and (ii) the capacity of infection, once initiated, to produce lethal disease. These studies provide further evidence for the polygenic nature of A/NWS neurovirulence.
Genetic recombination of the neurovirulent A/NWS/cc-p (HONM) and the non-neurovirulent A/Jap.305/57 (H2N2) influenza viruses in which hemagglutinin and neuraminidase were segregated (HON2, H2N1) were studied for neurovirulence in mice immunosuppressed with cyclophosphamide (CPA) which permitted full expression of virulence. Both HON2 and H2N1 recombinants replicated in the brain (in contrast to the H2N2 parent) and both produced lethal effects in CPA-treated animals. Therefore we conclude that A/NWS (HONM) neurovirulence is not exclusively linked with either the hemagglutinin or the neuraminidase of the virus. The HON2 and H2N1 recombinants have revealed the existence of two separate attributes of neurovirulence: (i) the capacity of virus to initiate intracerebral infection and (ii) the capacity of infection, once initiated, to produce lethal disease. These studies provide further evidence for the polygenic nature of A/NWS neurovirulence.
Two separately derived variants of the original WS influenza A virus (NWS [13 ] and WS-N [141) are uniquely able to replicate in and damage the brains of adult mice when inoculated intracerebrally in high dilution. Large doses of other influenza A viruses may produce "toxic" encephalopathy in mice (6) , but infective virus is not produced in adult mice and viral replication is abortive (11, 16) .
Earlier studies of genetic recombination employing NWS and WS-N in which only the hemagglutinin antigen was available as a marker (reviewed by Kilbourne, reference 9) have suggested that the neurovirulence of these variants is a composite trait with multiple determinants (i.e., polygenic) and that at least certain of these determinants are separable from the structural protein(s) defining the NWS, WS-N serotype in neutralization and hemagglutination inhibition tests. However, these early studies were technically limited by the lack of cell cultures and adequate plaque cloning systems.
It has been proposed that NWS neurovirulence may be associated with peculiarities of the neuraminidase of this strain (8) . The availability of a variety of NWS recombinants in this laboratory in which hemagglutin and neuraminidase antigens have been segregated prompted a systematic inquiry into the association of neurovirulence with either of these structural proteins of the virus. Our present study has been facilitated by the use of the immunosuppressant cyclophosphamide (CPA) for detecting minimal neurotropic effects (Mayer et al., manuscript in preparation), based on earlier studies with this drug in arbovirus infections (3). Neurovirulence tests. The neurovirulence of the viruses under study was assessed by (i) the capacity of the given virus to initiate infection in the mouse brain after intracerebral administration (icID ,), (ii) the titers of the infective virus in brain suspensions at intervals after infection, and (iii) the capacity to produce lethal disease (icILD5 o).
MATERIAL AND METHODS

Viruses
The intracerebral infectivity and lethality of the viruses were assessed by intracerebral inoculation of 16 control and 16 CPA-infected animals with 10-fold dilutions of the virus (0.03 ml). Two days later brains were removed from half of the mice in each group and tested for the presence or absence of egg-infective virus. The remaining animals were observed for 2 weeks for mortality.
Immunosuppressive treatment. Freshly prepared solutions of CPA, an agent of the nitrogen mustard class, N, N-bis/-chloroaethyl/-N, 0-propylene phosphoric acid ester diamine monohydrate (Cytoxan, Mead Johnson Laboratories, Evansville, Ind.), in deionized water were administered subcutaneously in 0.1-ml amounts. The dose of the drug used was 150 mg/kg of body weight. CPA was injected 24 hr before, 24 hr later, and on the 5th day after infection. The toxicity of the compound alone was negligible under the experimental conditions and was controlled in each experiment by observation of groups of 15 mice which received CPA subcutaneously and normal allantoic fluid intracerebrally.
Mice to which CPA was given are hereafter designated as CPA-mice, and mice to which CPA was not administered are designated as normal mice.
RESULTS
Enhancement of the lethality of the A/NWS/33 influenza virus in CPA-mice. The enhancing effect of CPA on the severity of intracerebral influenza virus infection in M-SPF mice was studied by using two variants of the A/NWS virus which differed in their passage history.
As shown in Table 2 , A/NWS/BP was only slightly more efficient than A/NWS/cc-p in initiating intracerebral infection in normal mice (i.e., the icID50 differed by only 1.3 logs), but lethal infection required only 10 50% egg infective doses (EID5 o) of A/NWS/BP, but more than 10 6.-5 EID50 of A/NWS/cc-p. However, administration of CPA in dosage of 150 mg/kg on days -1, +1, and +5 of infection markedly increased the susceptibility of mice to the lethal effects of A/NWS/cc-p (see last columns of Table 2 ). The effect on cumulative mortality in mice infected with 102 EID 5, of A/NWS/cc-p virus is illustrated -in Fig. 1 . CPA-treated mice so infected exhibited typical symptoms of central nervous system involvement, including paralysis and coma.
The increased morbidity and mortality in CPA-mice was associated with enhanced intracerebral replication of virus. The brains of mice inoculated intracerebrally with 103 EID50 of A/NWS/cc-p virus were found to contain 10 4 5 to 10 5-3 EID 50 of virus per 0.1 ml of 10% brain suspension 6 to 7 days after infection; brains of untreated mice similarly inoculated did not contain detectable egg-infective virus when examined at the same time interval.
Enhancement of disease (icLD, 0) with the more virulent A/NWS/BP strain was minimal (i.e., 1.0 log), and icID50 end points did not differ in CPA-treated and untreated animals.
With both NWS strains, the interval between inoculation and death was shortened by CPA administration, and the incubation period and mean death time were clearly related to the amount of virus inoculated, attesting to the specificity of the effect. Mortality was not seen in CPA-treated animals that were not infected, suggesting that CPA-induced mortality resulted from reduction in host resistance to NWS infection rather than from toxic effects of the drug.
Neurovirulence The replication patterns of the recombinant viruses mirrored those found with the neurovirulent A/NWS parent except that peak titers were 10-fold lower, and viral persistence was less affected by CPA administration (Fig. 3) .
Effect of CPA on the formation of hemagglutining virus in mouse brain. In view of evidence that incomplete (noninfective but hemagglutinating) virus is produced in mouse brain following inoculation of even non-neurovirulent influenza A virus (11) , it was of interest to examine (i) the capacity of non-neurovirulent A/Jap 305 to produce hemagglutinating virus in the brain and (ii) the possible influence of CPA on "unmasking" this effect. Therefore, groups of normal and CPA-mice (eight/group) were inoculated with 2.5 x 10 7 or 2.5 x 10 6 EID 5 o of A/Jap 305 virus. Two days later the presence of hemagglutinin and infective virus was sought in RDE-treated 10% suspensions of brains of individual animals.
In seven of eight mice inoculated with the higher virus concentration, neither infective or hemagglutinating activity was detected at 1:8 dilution. In a single animal, hemagglutinin at a titer of 1:64 and infective virus titering 10 ' l 5 EIDS 0/0.l ml was found. Neither infective nor hemagglutinating virus was detected in eight animals given the smaller viral inoculum. The results obtained in CPA mice were not appreciably different. In two of eight animals given the 2.5 x 107 EID50 inoculum, traces of hemagglutinating (1:8 titer) and infective (100 5 EID 5 ) virus were demonstrable.
The ability of the method employed to demonstrate viral hemagglutinin in brain suspensions was confirmed in similar experiments with a neurovirulent recombinant virus in which HA was readily detected. With recombinant A/NWS (H0)-Jap 305 (N2) the geometric mean HA titer at 2 days was 1: 24 and was increased fivefold in CPA-mice.
In other experiments it was shown that the infectivity of the parental and recombinant viruses was unaffected by incubation of virus with equal volumes of 5% normal mouse brain suspension for 90 min at 36 C. Infectivity titers (idID s) were not increased by RDE treatment of 10% brain suspensions obtained 2 days after infection.
Neurovirulence of A/NWS recombinants The HON2 and H2N1 recombinants have revealed the existence of two separate attributes of neurovirulence, (ii) the capacity of virus to initiate intracerebral infection (as revealed by EID 5 0/ic 50 ratios) and (ii) the capacity of int'ection, once engendered, to produce lethal disease (EID 5/LD 5o ratio). These observations provide more compelling evidence of the polygenic nature of A/NWS virus neurovirulence than the nonexclusive association of' virulence with A/NWS HA or NA, which could be explained by linkage of virulence with other of' the viral polypeptides. We shall search further for such associations, which were not disclosed in our studies with recombinant A/CAM (HI)-CAM (NI) ( Table 5) . We also plan complementation studies with the HON2 and H2N1 recombinants to determine whether full restoration of' neurovirulence occurs equivalent to that of parental A/NWS virus.
